News
11/20/2023
A study for people with GI cancers and two studies for people with advanced and early-stage lung cancer hope to develop better treatment options with the help of immunotherapy.
11/3/2023
Providence researchers say comprehensive genomic profiling can be pivotal in identifying gene mutations in a patient and tailoring personalized treatment strategies.
11/20/2023
SITC 2023 provides a glimpse into scientific advances and breakthroughs in cancer immunotherapy by researchers from around the world.
10/20/2023
Providence Cancer Institute lung cancer expert to present a virtual education talk on lung cancer screening, prevention and latest treatments.
10/12/2023
Two new studies available at Earle A. Chiles Research Institute, at division of Providence Cancer Institute of Oregon, to evaluate new treatments for triple-negative breast cancer.
10/4/2023
Providence Cancer Institute of Oregon, and research director, Earle A. Chiles Research Institute, Walter J. Urba, M.D., Ph.D., receives award for his contributions to science and community.
9/25/2023
Providence Cancer Institute celebrates Advanced Practice Providers Week from September 25 to 29 and recognizes their important contributions more than 25 clinics and programs.
9/22/2023
Providence Cancer Institute of Oregon announces new division director and deputy director of Hematology and Medical Oncology.
9/18/2023
For Gynecologic Cancer Awareness Month, Providence Cancer Institute highlights a clinical trial that evaluates the safety and effectiveness of a new oral treatment for grade 1 endometrial cancer.
7/27/2023
In 2021, Dr. Nicole Schmidt was driving around a curve when she saw a car headed straight for her. The crash sent her to a trauma center and started a journey of healing, learning and becoming.
7/10/2023
A phase II trial tests FOLFOX or CAPOX versus FOLFIRINOX in patients with locally advanced rectal cancer, and a phase I trial evaluates TBio-4101 in patients with advanced solid tumors.
7/3/2023
Final outcomes from a Providence Cancer Institute-sponsored phase Ib trial evaluating pembrolizumab with either weekly paclitaxel or flat-dose capecitabine in treating patients with metastatic TNBC.